Company · CIK 0001650648 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
4D Molecular Therapeutics, Inc. · FDMT
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 SForm 4 → | Sep 22, 6:43 pm EDT | Scott BizilyChief Legal Officer | 1,635 | $13.65 | $22,318 | 8,617 | −15.9% | 10b5-1 late |
| Sep 16, 2026 MForm 4 → | Sep 22, 6:43 pm EDT | Scott BizilyChief Legal Officer | 1,635 | $4.14 | $6,769 | 10,252 | — | 10b5-1 late |
| Sep 14, 2026 SForm 4 → | Sep 16, 5:13 pm EDT | David KirnSee Remarks, Director | 58,333 | $13.90 | $811,004 | 767,486 | −7.06% | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 3, 6:55 pm EDT | Scott BizilyChief Legal Officer | 584 | $14.00 | $8,176 | 8,617 | −6.35% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 3, 6:55 pm EDT | Scott BizilyChief Legal Officer | 584 | $6.49 | $3,790 | 9,201 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 MForm 4 → | Sep 22, 6:43 pm EDT | Scott BizilyChief Legal Officer | 1,635 | — | — | 58,066 | — | 10b5-1 late |
| Sep 1, 2026 MForm 4 → | Sep 3, 6:55 pm EDT | Scott BizilyChief Legal Officer | 584 | — | — | 2,959 | — | 10b5-1 |